Clinical and Translational Medicine, Год журнала: 2024, Номер 14(10)
Опубликована: Окт. 1, 2024
Язык: Английский
Journal of Hepatology, Год журнала: 2024, Номер 81(3), С. 492 - 542
Опубликована: Июнь 7, 2024
Язык: Английский
Процитировано
314
Obesity Facts, Год журнала: 2024, Номер 17(4), С. 374 - 444
Опубликована: Янв. 1, 2024
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty (NAFLD), is defined as (SLD) in the presence of one or more cardiometabolic risk factor(s) and absence harmful alcohol intake. The spectrum MASLD includes steatosis, metabolic steatohepatitis (MASH, NASH), fibrosis, cirrhosis MASH-related hepatocellular carcinoma (HCC). This joint EASL-EASD-EASO guideline provides an update on definitions, prevention, screening, diagnosis treatment for MASLD. Case-finding strategies with using non-invasive tests, should be applied individuals factors, abnormal enzymes, and/or radiological signs hepatic particularly type 2 diabetes (T2D) obesity additional factor(s). A stepwise approach blood-based scores (such FIB-4) and, sequentially, imaging techniques transient elastography) suitable to rule-out/in advanced which predictive liver-related outcomes. In adults MASLD, lifestyle modification - including weight loss, dietary changes, physical exercise discouraging consumption well optimal management comorbidities use incretin-based therapies (e.g. semaglutide, tirzepatide) T2D obesity, if indicated advised. Bariatric surgery also option obesity. If locally approved dependent label, non-cirrhotic MASH significant fibrosis (stage ≥2) considered a MASH-targeted resmetirom, demonstrated histological effectiveness acceptable safety tolerability profile. No pharmacotherapy can currently recommended cirrhotic stage. Management adaptations drugs, nutritional counselling, surveillance portal hypertension HCC, transplantation decompensated cirrhosis.
Язык: Английский
Процитировано
59
Hepatology, Год журнала: 2024, Номер unknown
Опубликована: Фев. 13, 2024
Liver cancer is the third leading cause of cancer-related deaths and ranks as sixth most prevalent type globally. NAFLD or metabolic dysfunction-associated steatotic liver disease, its more severe manifestation, NASH steatohepatitis (MASH), pose a significant global health concern, affecting approximately 20%-25% population. The increased prevalence disease MASH parallel to increasing rates obesity-associated diseases, including 2 diabetes, insulin resistance, fatty diseases. can progress MASH-related HCC (MASH-HCC) in about 2% cases each year, influenced by various factors such genetic mutations, carcinogen exposure, immune microenvironment, microbiome. MASH-HCC exhibits distinct molecular characteristics compared other causes affects both men women equally. management early intermediate-stage typically involves surgery locoregional therapies, while advanced treated with systemic anti-angiogenic therapies checkpoint inhibitors. In this comprehensive review, we consolidate previous research findings also providing current insights into intricate processes underlying development. We delve MASH-HCC-associated variations somatic progression models, multiomics analysis, immunological microenvironmental impacts, discuss targeted/combined overcome evasion biomarkers recognize treatment responders. By furthering our comprehension mechanisms MASH-HCC, goal catalyze advancement potent strategies, ultimately enhanced patient outcomes.
Язык: Английский
Процитировано
41
Gut Microbes, Год журнала: 2024, Номер 16(1)
Опубликована: Фев. 1, 2024
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic disease, and its prevalence has increased worldwide in recent years. Additionally, there a close relationship between MASLD gut microbiota-derived metabolites. However, mechanisms of metabolites are still unclear. We demonstrated decreased indole-3-propionic acid (IPA) indole-3-acetic (IAA) feces patients with hepatic steatosis compared to healthy controls. Here, IPA IAA administration ameliorated inflammation an animal model WD-induced by suppressing NF-κB signaling pathway through reduction endotoxin levels inactivation macrophages. Bifidobacterium bifidum metabolizes tryptophan produce IAA, B. effectively prevents production IAA. Our study demonstrates that derived from microbiota have novel preventive or therapeutic potential for treatment.
Язык: Английский
Процитировано
31
Metabolites, Год журнала: 2024, Номер 14(7), С. 366 - 366
Опубликована: Июнь 28, 2024
Nonalcoholic fatty liver disease (NAFLD) poses an emerging threat topublic health. steatohepatitis (NASH) is reported to be the most rapidly rising cause of hepatocellular carcinoma in western world. Recently, a new term has been proposed: metabolic dysfunction-associated steatotic (MASLD). The introduction this terminology sparked debate about interchangeability these terms. pathogenesis NAFLD/MASLD thought multifactorial, involving both genetic and environmental factors. Among factors, alterations gut microbiota dysbiosis have recently garnered significant attention. In context, review will further discuss gut-liver axis, which refers bidirectional interaction between human liver. Additionally, therapeutic potential probiotics, particularly next-generation probiotics genetically engineered bacteria, explored. Moreover, role prebiotics, synbiotics, postbiotics, phages as well fecal transplantation analyzed. Particularly for lean patients with NAFLD/MASLD, who limited treatment options, approaches that modify diversity composition may hold promise. However, due ongoing safety concerns modulate microbiota, large-scale studies are necessary better assess their efficacy treating NAFLD/MASLD.
Язык: Английский
Процитировано
22
Journal of Agricultural and Food Chemistry, Год журнала: 2024, Номер 72(5), С. 2573 - 2584
Опубликована: Янв. 19, 2024
Hyperuricemia (HUA) is a metabolic disorder characterized by an increase in the concentrations of uric acid (UA) bloodstream, intricately linked to onset and progression numerous chronic diseases. The tripeptide Pro-Glu-Trp (PEW) was identified as xanthine oxidase (XOD) inhibitory peptide derived from whey protein, which previously shown mitigate HUA suppressing UA synthesis enhancing renal excretion. However, effects PEW on intestinal excretion pathway remain unclear. This study investigated impact alleviating rats perspective transport, gut microbiota, barrier. results indicated that inhibited XOD activity serum, jejunum, ileum, ameliorated morphology changes oxidative stress, upregulated expression ABCG2 GLUT9 small intestine. reversed microbiota dysbiosis decreasing abundance harmful bacteria (e.g., Bacteroides, Alloprevotella, Desulfovibrio) increasing beneficial microbes Muribaculaceae, Lactobacillus, Ruminococcus) elevated concentration short-chain fatty acids. occludin ZO-1 decreased serum IL-1β, IL-6, TNF-α levels. Our findings suggested supplementation excretion, modulating restoring barrier function.
Язык: Английский
Процитировано
17
Obesity Reviews, Год журнала: 2024, Номер 25(6)
Опубликована: Фев. 26, 2024
Summary Chronic inflammation of adipose tissue is a prominent characteristic many metabolic diseases. Lipid metabolism in consistently dysregulated during inflammation, which characterized by substantial infiltration proinflammatory cells and high cytokine concentrations. Adipose caused variety endogenous factors, such as mitochondrial dysfunction, reactive oxygen species (ROS) production, endoplasmic reticulum (ER) stress, cellular senescence, ceramides biosynthesis mediators lipopolysaccharides (LPS) signaling. Additionally, the gut microbiota also plays crucial role regulating inflammation. Essentially, arises from an imbalance adipocyte regulation immune cells. Specific inflammatory signals, including nuclear factor‐κB (NF‐κB) signaling, inflammasome signaling inflammation‐mediated autophagy, have been shown to be involved regulation. The pathogenesis diseases chronic (obesity, insulin resistance, atherosclerosis nonalcoholic fatty liver disease [NAFLD]) recent research regarding potential therapeutic targets for these conditions are discussed this review.
Язык: Английский
Процитировано
14
Nature Reviews Gastroenterology & Hepatology, Год журнала: 2024, Номер 21(8), С. 556 - 571
Опубликована: Июнь 3, 2024
Язык: Английский
Процитировано
14
Cell Host & Microbe, Год журнала: 2024, Номер 32(8), С. 1280 - 1300
Опубликована: Авг. 1, 2024
Язык: Английский
Процитировано
14
Scientific Reports, Год журнала: 2024, Номер 14(1)
Опубликована: Сен. 27, 2024
Язык: Английский
Процитировано
9